Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced that management will participate in the following upcoming investor conferences:
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences:
The Stifel 2020 Virtual Healthcare Conference
- Management will present on Monday, November 16 at 4:40 p.m. Eastern Time.
The 11th Annual Craig-Hallum Alpha Select Conference
- Management will participate in virtual 1x1 meetings on Tuesday, November 17. There will be no formal presentation.
The Canaccord Genuity Virtual MedTech & Diagnostics Forum
- Management will participate in virtual 1x1 meetings on Thursday, November 19. There will be no formal presentation.
The 32nd Annual Piper Sandler Healthcare Conference
- Management will participate in a fireside chat, which will be accessible via the conference platform throughout the duration of the event: from Tuesday, December 1 until Thursday, December 3.
Audio webcasts of the presentations will be provided under the ‘Company Events’ section of the Apyx Medical Corporation investor relations website at https://apyxmedical.com/investor_relations/. Archives of the webcasts will be available for replay following the conferences.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005609/en/
Investor Relations Contact:
Westwicke Partners on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
Source: Apyx Medical Corporation
View this news release online at:
http://www.businesswire.com/news/home/20201103005609/en
